UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2021

Privia Health Group, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or other jurisdiction of incorporation or organization)

81-3599420 (I.R.S. Employer Identification No.)

950 N. Glebe Rd., Suite 700 Arlington, Virginia (Address of Principal Executive Offices)

001-40365 (Commission File No.)

> 22203 (Zip Code)

(571) 366-8850 Registrant's telephone number, including area code

Not Applicable (Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) □ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) □ Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value per share	PRVA	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

 \mathbf{X}

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Item 7.01 Regulation FD Disclosure.

We are furnishing this Current Report on Form 8-K to furnish materials that will be provided at meetings with institutional investors or analysts. The materials are attached as Exhibit 99.1 to this Current Report on Form 8-K, are incorporated into this Item 7.01 by reference and are available on our investor relations website at <u>inpriviahealth.com</u>. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later company filing, or other means.

The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.

We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit:	
Exhibit No	

non.	
Exhibit No.	Description
99.1	Privia Health Group, Inc. Investor Presentation Slides - June 2021

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRIVIA HEALTH GROUP, INC.

By: /s/ David Mountcastle

Name: David Mountcastle Title: Chief Financial Officer and Authorized Officer

Date: June 16, 2021

EXHIBIT INDEX

Exhibit Number	Description
99.1	Privia Health Group, Inc. Investor Presentation Slides - June 2021



Disclaimer

Forward-Looking Statements

This presentation contains forward-looking statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results that include, but are not limited to: 2021 financial guidance and other projections and forecasts. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company's control) or other assumptions that may uncertainties include, but are not limited to: 2021 financial guidance and other projections and forecasts. These forward-looking statements include, but are not limited to: be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to; those factors described in filings with the Securities and Exchange Commission ("SEC"), including those under "Risk Factors" therein. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date made. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Use of Non-GAAP Financial Information

In order to provide investors with greater insight, promote transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision-making, the Company supplements its condensed consolidated financial statements presented on a GAAP basis herein with certain non-GAAP financial information, including: Care Margin; Platform Contribution; Platform Contribution margin; Adjusted EBITDA; and Adjusted EBITDA margin. Reconciliations of these non-GAAP measures to their most directly comparable GAAP measures are included in the financial schedules in the Appendix of this presentation, as well as in the Company's quarterly financial press releases and related Form 8-K filings with the SEC. This information can be accessed for free by visiting www.priviahealth.com or www.sec.gov.

Management has not reconciled forward-looking non-GAAP measures to its most directly comparable GAAP measure of Operating Income and Net Income. This is because the Company cannot predict with reasonable certainty and without unreasonable efforts the ultimate outcome of Care Margin, Platform Contribution or Adjusted EBITDA due to market-related assumptions that are not within our control as well as certain legal or advisory costs, tax costs or other costs that may arise. For these reasons, management is unable to assess the probable significance of the unavailable information, which could materially impact the amount of the future directly comparable GAAP measures.

OPRIVIA.

Our Mission and Vision

OUR MISSION

Transform healthcare to enable doctors and their teams to focus on keeping people healthy

WHO WE ARE

National physician platform transforming the healthcare delivery experience

WHAT WE DO

Provide tailored solutions for physicians and providers, creating value and securing their future


OPRIVIA.

WE KNOW doctors.

WE ENABLE better outcomes.

TOGETHER we move markets.

Privia Health: Investment Highlights




Moving Markets Toward Value -Based Care At Scale



Building a National Footprint




Significant Whitespace Exists Across Our End Markets




OPRIVIA. Source: Kaiser Family Foundation, Nephron Research "The Dawn of Physician Enablement: Defining Healthcare in the 2020 s." January 20, 2021. Statista.

Proven, Scalable and Flexible Operating Model


- · Single TaxID Medical Group in each local market- a primary care centric delivery network in each market
- Management services and clinical organization enabled by the Privia Technology Solution
- Market specific strategies Accountable Care Organizations and ancillary services based on market dynamics
- Recognize practice collections across all of our providers
- Under fee-for-service contracts, Privia keeps a percentage of total collections
- Under value-based care constructs, Privia collects a per member per month ("PMPM") fee and a portion of the shared savings generated



Differentiated Model Organizes Cost -Efficient Provider Networks




Tech-Driven Physician Enablement Platform At Scale




OPRIVIA.


Differentiated Value -Based Care (VBC) Opportunity




Methodical Process Helps Providers Move Towards Value




Proprietary, End-to-End Tech Solution Enables Providers to Practice More Efficiently and Focus on Patient Care





The Privia Technology Solution Creates an Integrated Experience for Providers and Patients




Delivering Demonstrable Value to Our Providers








The Privia Platform is Scaling Rapidly



OPRIVIA. *The 2021 guidance contained in this slide represents midpoint of guidance provided on May 27, 2021, which is not being updated or confirmed hereby.

Improving Margins Over Time



FY'21 Guidance as of May 27, 2021

(\$ in millions)	nillions) FY 2020 Actual FY 2021 Guidance		Y - Y % Change from FY 2020
		Low High	Low High
Implemented Providers	2,550	2,850 2,900	11.8% 13.7%
Attributed Lives	682,000	730,000 750,000	7.0% 10.0%
Practice Collections	\$ 1,301.1	\$ 1,445 \$ 1,465	11.1% 12.6%
GAAP Revenue	\$ 817.1	\$ 860 \$ 880	5.3% 7.7%
Care Margin	\$ 187.6	\$ 215 \$ 221	14.6% 17.8%
Platform Contribution	\$ 82.6	\$ 93 \$ 98	12.6% 18.6%
Adjusted EBITDA	\$ 29.4	\$ 34 \$ 38	15.6% 29.3%

CPRIVIA. *FY 2021 guidance was provided on May 27, 2021, and is not being updated or confirmed hereby.


20

Other FY'21 Guidance Assumptions


- Fully diluted weighted average shares outstanding of 110 120M, including pre-IPO period
- Non-cash stock compensation expense of \$195 \$205M in 2Q'21 and \$245 \$255M for FY'21*
- Pro forma 1Q'21 cash of ~\$293.9M** with total debt of \$33.9M
- Capital expenditures of < \$1M
- Effective tax rate of 25 27%

Note: FY 2021 guidance was provided on May 27, 2021, and is not being updated or confirmed hereby. * Non-cash stock compensation expense primarily related to the stock option plan modification and additional equity grants in connection with the IPO ** Pro forma cash includes \$819 million in cash and cash equivalents at March 31, 2021 and approximately \$2120 million in net proceeds from the Privia Health initial public offering and private placement that closed on May 3, 2021


OPRIVIA.



Privia Health: Investment Highlights










Case Study: Establishing an Anchor Partnership in a New Market with Health System "A" and Driving Growth



Reconciliation of Operating Income to Care Margin ¹

	2020 Ye	ar Ended Decembe 2019	r 31, 2018
(in thousands)			-
Operating Income	\$ 25,380	\$ 16,062	\$ 2,155
Depreciation and amortization	1,843	1,427	1,070
General and administrative	44,016	41,827	41,497
Sales and marketing	11,343	9,156	11,737
Cost of platform	105,006	95,256	73,227
Total care margin	\$187,588	\$163,728	\$129,686

OPRIVIA. (1) Care Margin is total revenue less the sum of physician and practice expense.

28

Reconciliation of Operating Income to Care Margin ¹

	For the Three Months Ended March 31,			
(unaudited and \$ in thousands)	-	2021		2020
Operating income	\$	7,907	s	6,496
Depreciation and amortization		445		338
General and administrative		13,996		10,989
Sales and marketing		3,184		2,452
Cost of platform		26,962		27,561
Care margin	S	52,494	\$	47,836

OPRIVIA. (1) Care Margin is total revenue less the sum of physician and practice expense.

29

Reconciliation of Operating Income to Platform Contribution ²

	Year Ended December 31,		
	2020	2019	2018
(in thousands)			
Operating Income	\$25,380	\$16,062	\$ 2,155
Depreciation and amortization	1,843	1,427	1,070
General and administrative	44,016	41,827	41,497
Sales and marketing	11,343	9,156	11,737
Total platform contribution	\$82,582	\$68,472	\$ 56,459

OPRIVIA. (2) Platform Contribution is total revenue less the sum of physician and practice expense and cost of platform.



Reconciliation of Operating Income to Platform Contribution ²

	For the Three Months Ended March 31,				
(unaudited; \$ in thousands)		2021		2020	
Operating income	\$	7,907	\$	6,496	
Depreciation and amortization		445		338	
General and administrative		13,996		10,989	
Sales and marketing		3,184		2,452	
Platform contribution	\$	25,532	\$	20,275	

OPRIVIA. (2) Platform Contribution is total revenue less the sum of physician and practice expense and cost of platform.

31

Reconciliation of Net Income to Adjusted EBITDA ³

	Yea	r Ended December 3	1,
(in thousands)	2020	2019	2018
Net income (loss)	\$31,244	\$ 8,244	\$(3,044)
Net loss attributable to non-controlling interests	(340)	(299)	(1,145)
(Benefit from) provision for income taxes	(7,441)	1,207	(76)
Interest expense	1,917	6,910	6,420
Depreciation and amortization	1,843	1,427	1,070
Stock-based compensation(1)	484	207	1,941
Severance costs ⁽²⁾	11	32	2,987
Other expenses(3)	1,654	398	778
Adjusted EBITDA	\$29,372	\$18,126	\$ 8,931

(3) Adjusted EBITDAis net income (loss) attributable to Privia Health Group, Inc. shareholders and subsidiaries excluding minority interests, provision (benefit) for income taxes, interest income, interest expense, depreciation and amortization, stock-based compensation, severance charges and other non-recurring expenses. Note: 2020 actuals exclude public company costs.

Reconciliation of Net Income to Adjusted EBITDA ³

	For the Three Months Ended March 31,				
(unaudited; amounts in thousands)		2021	2020		
Net income	s	5,398	\$	5,414	
Net income (loss) attributable to non-controlling interests		218		(85)	
Provision for income taxes		2,000		700	
Interest expense		291		467	
Depreciation and amortization		445		338	
Stock-based compensation		101		121	
Other expenses		1,494		100	
Adjusted EBITDA	\$	9,947	\$	7,055	

OPRIVIA.

(3) Adjusted EBITDAis net income (loss) attributable to Privia Health Group, Inc. shareholders and subsidiaries excluding minority interests, provision (benefit) for income taxes, interest income, interest expense, depreciation and amortization, stock-based compensation, severance charges and other non-recurring expenses.

33

PRIVIA.

Thank You

PriviaHealth.com

Contact: Robert P. Borchert SVP, Investor & Corporate Communications robert.borchert@priviahealth.com Phone: 817.783.4841